Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment.
acute myeloid leukemia
bone marrow microenvironment
chemoresistance
extracellular vesicles
stroma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
accepted:
17
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Extracellular vesicle (EV) trafficking provides for a constitutive mode of cell-cell communication within tissues and between organ systems. Different EV subtypes have been identified that transfer regulatory molecules between cells, influencing gene expression, and altering cellular phenotypes. Evidence from a range of studies suggests that EV trafficking enhances cell survival and resistance to chemotherapy in solid tumors. In acute myeloid leukemia (AML), EVs contribute to the dynamic crosstalk between AML cells, hematopoietic elements and stromal cells and promote adaptation of compartmental bone marrow (BM) function through transport of protein, RNA, and DNA. Careful analysis of leukemia cell EV content and phenotypic outcomes provide evidence that vesicles are implicated in transferring several known key mediators of chemoresistance, including miR-155, IL-8, and BMP-2. Here, we review the current understanding of how EVs exert their influence in the AML niche, and identify research opportunities to improve outcomes for relapsed or refractory AML patients.
Identifiants
pubmed: 32117744
doi: 10.3389/fonc.2020.00090
pmc: PMC7033644
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
90Subventions
Organisme : NCI NIH HHS
ID : F30 CA247601
Pays : United States
Informations de copyright
Copyright © 2020 Nehrbas, Butler, Chen and Kurre.
Références
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Blood. 2013 Oct 3;122(14):2443-52
pubmed: 23982172
Hematology Am Soc Hematol Educ Program. 2012;2012:43-8
pubmed: 23233559
Blood Rev. 2017 Jan;31(1):63-76
pubmed: 27639498
J Cancer Res Clin Oncol. 2016 Jan;142(1):77-87
pubmed: 26113450
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Front Oncol. 2017 Oct 30;7:255
pubmed: 29164055
Cancer Sci. 2018 Mar;109(3):629-641
pubmed: 29285843
Curr Treat Options Oncol. 2017 Mar;18(3):17
pubmed: 28286924
Carcinogenesis. 2010 Dec;31(12):2049-57
pubmed: 20876285
Leukemia. 2007 Mar;21(3):427-38
pubmed: 17215852
J Hematol Oncol. 2018 Jan 22;11(1):11
pubmed: 29357914
Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):269-77
pubmed: 22285729
Oncogene. 2019 Jun;38(23):4429-4451
pubmed: 30814684
Cancer Biol Ther. 2012 Aug;13(10):890-8
pubmed: 22785209
Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13
pubmed: 19966785
Oncotarget. 2016 Apr 5;7(14):18736-49
pubmed: 26934650
Bone Marrow Transplant. 2016 Nov;51(11):1431-1438
pubmed: 27295272
Acta Pharmacol Sin. 2018 Apr;39(4):501-513
pubmed: 29219950
Biochem Biophys Res Commun. 2017 Aug 19;490(2):406-414
pubmed: 28623135
Biomaterials. 2017 Nov;144:119-129
pubmed: 28834763
Cancer Res. 2008 Oct 15;68(20):8191-4
pubmed: 18922889
Semin Oncol. 2008 Aug;35(4):324-5
pubmed: 18692682
J Clin Invest. 2013 Jun;123(6):2395-407
pubmed: 23676502
Clin Cancer Res. 2005 Apr 1;11(7):2540-6
pubmed: 15814631
Blood. 2010 Oct 7;116(14):2484-93
pubmed: 20570856
Blood. 2014 Oct 30;124(18):2834-46
pubmed: 25139351
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Sci Rep. 2016 May 31;6:27157
pubmed: 27244080
Br J Haematol. 2014 Mar;164(6):767-78
pubmed: 24405087
Leukemia. 2014 Oct;28(10):1978-1987
pubmed: 24637335
Mol Cell Proteomics. 2016 Apr;15(4):1281-98
pubmed: 26801919
J Biol Chem. 2002 Aug 9;277(32):29132-8
pubmed: 12042301
J Clin Med. 2015 Apr;4(4):665-95
pubmed: 25932335
Front Mol Neurosci. 2017 Oct 17;10:333
pubmed: 29089870
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
Leuk Res. 2017 Nov;62:70-76
pubmed: 28987820
Front Immunol. 2014 Apr 10;5:160
pubmed: 24782865
Sci Signal. 2016 Sep 06;9(444):ra88
pubmed: 27601730
Int J Cancer. 2019 Jun 15;144(12):3070-3085
pubmed: 30556600
Haematologica. 2018 Mar;103(3):382-394
pubmed: 29439185
Br J Cancer. 2017 Feb 28;116(5):609-619
pubmed: 28152544
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679949
J Biol Chem. 2014 Feb 14;289(7):3869-75
pubmed: 24398677
Leukemia. 2019 Apr;33(4):918-930
pubmed: 30206307
Semin Hematol. 2015 Jul;52(3):200-6
pubmed: 26111467
Sci Rep. 2017 Oct 31;7(1):14684
pubmed: 29089618
Leuk Lymphoma. 2018 Apr;59(4):790-802
pubmed: 28679300
Mol Pharmacol. 2013 Feb;83(2):399-405
pubmed: 23166305
Cell Mol Neurobiol. 2013 Nov;33(8):1143-8
pubmed: 24046143
Blood. 2002 Oct 1;100(7):2393-8
pubmed: 12239147
Leukemia. 2012 Jul;26(7):1462-70
pubmed: 22354205
Sci Rep. 2018 Jan 16;8(1):829
pubmed: 29339789
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):348-355
pubmed: 27913501
Oncotarget. 2015 Oct 13;6(31):31508-21
pubmed: 26375552
Leuk Res. 2005 Feb;29(2):185-96
pubmed: 15607368
Blood. 2005 Jan 1;105(1):54-60
pubmed: 15345597
Cancer Lett. 2014 Jun 28;348(1-2):71-6
pubmed: 24657661
Nat Commun. 2019 Aug 26;10(1):3854
pubmed: 31451692
Antioxid Redox Signal. 2017 Nov 20;27(15):1217-1234
pubmed: 28537430
Cancer Cell. 2019 Jan 14;35(1):33-45.e6
pubmed: 30645975
J Extracell Vesicles. 2017 Sep 26;6(1):1378056
pubmed: 29184623
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818763450
pubmed: 29681222
Br J Haematol. 2016 Mar;172(6):983-6
pubmed: 26095727
Nature. 2017 May 4;545(7652):98-102
pubmed: 28445461
Blood. 2013 Nov 28;122(23):3767-77
pubmed: 24100446
Blood. 2015 Aug 27;126(9):1106-17
pubmed: 26100252
J Transl Med. 2013 Apr 10;11:94
pubmed: 23574623
Onco Targets Ther. 2019 Mar 11;12:1937-1945
pubmed: 30881045
Leukemia. 2005 Aug;19(8):1345-9
pubmed: 15959528
J Clin Invest. 2016 Dec 1;126(12):4537-4553
pubmed: 27797340
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
Sci Signal. 2017 Jun 06;10(482):
pubmed: 28588081
Cell Stem Cell. 2018 Jan 4;22(1):64-77.e6
pubmed: 29276143
Oxid Med Cell Longev. 2013;2013:972913
pubmed: 23766865
Sci Rep. 2017 Mar 03;7:43109
pubmed: 28256505
Life Sci. 2019 Mar 15;221:187-195
pubmed: 30716336
Curr Hematol Malig Rep. 2017 Dec;12(6):530-536
pubmed: 28397032
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Clin Cancer Res. 2016 Jul 15;22(14):3537-49
pubmed: 26858310
Oncotarget. 2015 Mar 20;6(8):5490-500
pubmed: 25823927
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):37-44
pubmed: 29222235
Cytokine Growth Factor Rev. 2018 Oct;43:8-15
pubmed: 30181021
Cancer Res. 2013 Jan 15;73(2):918-29
pubmed: 23149911
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
Int J Cancer. 2008 Jul 15;123(2):372-379
pubmed: 18449891
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Immunol Cell Biol. 2019 Feb;97(2):229-235
pubmed: 30422351